Zosuquidar is an investigational antineoplastic agent classified as a potent dual inhibitor that targets tubulin polymerization and the DNA topoisomerase I enzyme complex. Currently in development for… Read more
Zosuquidar is an investigational antineoplastic agent classified as a potent dual inhibitor that targets tubulin polymerization and the DNA topoisomerase I enzyme complex. Currently in development for the treatment of various solid tumors, such as non-small cell lung cancer and hepatocellular carcinoma, the compound requires rigorous analytical oversight throughout its clinical evaluation. This category provides essential reference standards, including Zosuquidar trihydrochloride and stable isotope labelled compounds like deuterated isotopologues, which are critical for accurate pharmaceutical analysis. Laboratories utilize these high-quality materials for impurity profiling, method validation, and conducting pharmacokinetic studies necessary for regulatory submissions. By employing these precise reference materials, researchers can ensure the consistency and reliability of data required for assessing the safety and efficacy of this therapeutic candidate during its ongoing development.